Clene (CLNN)

Company Profile

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.

Company profile

Ticker

CLNN, CLNNW

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

Chelsea Worldwide Inc.

SEC CIK

0001822791

Corporate docs

Articles of Incorporation & Bylaws

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Clene Nanomedicine, Inc. • Clene Australia Pty Ltd • dOrbital, Inc. • Clene Netherlands B.V. ...

CLNN stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$10.50

Low target

$8.00

High target

$13.00

Latest filings (excl ownership)

View all

Departure of Directors or Certain Officers

17 Mar 23

8-K

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

CNM-Au8® ASSOCIATED WITH DELAYED TIME TO KEY CLINICAL PROGRESSION EVENTS AT SIX MONTHS SUPPORTING A SURVIVAL BENEFIT IN THE HEALEY ALS PLATFORM TRIAL

9 Mar 23

424B5

Prospectus supplement for primary offering

Regulation FD Disclosure

6 Mar 23

8-K

Entry into a Material Definitive Agreement

3 Mar 23

8-K

Regulation FD Disclosure

27 Feb 23

Latest ownership filings

View all

Financial summary

Financial statements Chart CLNN financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	18.39 mm	18.39 mm	18.39 mm	18.39 mm	18.39 mm	18.39 mm
Cash burn (monthly)	(no burn)	2.66 mm	3.89 mm	4.13 mm	2.57 mm	3.25 mm
Cash used (since last report)	n/a	7.17 mm	10.47 mm	11.13 mm	6.92 mm	8.75 mm
Cash remaining	n/a	11.22 mm	7.92 mm	7.26 mm	11.47 mm	9.64 mm
Runway (months of cash)	n/a	4.2	2.0	1.8	4.5	3.0

Beta Read what these cash burn values mean

Financial data from Clene earnings reports.

Institutional ownership, Q4 2022

CLNN institutional ownership history Ownership history

5.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	35	45	-22.2%
Opened positions	8	16	-50.0%
Closed positions	18	15	+20.0%
Increased positions	8	8	–
Reduced positions	8	13	-38.5%

13F shares	Current	Prev Q	Change
Total value	2.29 bn	14.70 mm	+15449.5%
Total shares	3.08 mm	4.26 mm	-27.7%
Total puts	334.25 k	6.42 mm	-94.8%
Total calls	57.80 k	1.15 mm	-95.0%
Total put/call ratio	5.8	5.6	+3.7%

Largest owners	Shares	Value	Change
Vanguard	932.06 k	$932.06 mm	+0.0%
Kepos Capital	344.43 k	$344.00 k	-13.9%
Laird Norton Trust	268.58 k	$268.58 mm	0.0%
Geode Capital Management	230.81 k	$230.00 k	+4.3%
Soltis Investment Advisors	218.92 k	$218.92 mm	0.0%
BLK Blackrock	185.25 k	$185.25 mm	+0.7%
Group One Trading	126.34 k	$126.34 mm	NEW
Atom Investors	123.05 k	$123.05 mm	NEW
Millennium Management	117.14 k	$117.00 k	-44.2%
Bridgeway Capital Management	100.77 k	$100.77 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Tang Capital Management	0.00	-1.10 mm	EXIT
Group One Trading	126.34 k	+126.34 k	NEW
Atom Investors	123.05 k	+123.05 k	NEW
Morgan Jess S & Co	0.00	-112.00 k	EXIT
Bridgeway Capital Management	100.77 k	+100.77 k	NEW
Millennium Management	117.14 k	-92.95 k	-44.2%
Caption Management	0.00	-81.72 k	EXIT
STT State Street	68.05 k	+68.05 k	NEW
Kepos Capital	344.43 k	-55.57 k	-13.9%
RY Royal Bank Of Canada	0.00	-52.02 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CLNN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 Feb 23	Mark Mortenson	Stock Options Common Stock	Grant	Acquire A	No	No	1.28	75,000	96.00 k	75,000
17 Feb 23	Morgan R Brown	Stock Options Common Stock	Grant	Acquire A	No	No	1.28	125,000	160.00 k	125,000
2 Feb 23	Alison Mosca	Stock Options Common Stock	Grant	Acquire A	No	No	1.62	12,430	20.14 k	12,430
2 Feb 23	John Henry Stevens	Stock Options Common Stock	Grant	Acquire A	No	No	1.62	9,373	15.18 k	9,373
2 Feb 23	Shalom Jacobovitz	Stock Options Common Stock	Grant	Acquire A	No	No	1.62	12,124	19.64 k	12,124